IRIS
CEA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.617
AS - Asia 1.964
NA - Nord America 1.771
Continente sconosciuto - Info sul continente non disponibili 384
SA - Sud America 172
AF - Africa 31
OC - Oceania 3
Totale 18.942
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 14.247
US - Stati Uniti d'America 1.658
SG - Singapore 697
CN - Cina 472
VN - Vietnam 369
BD - Bangladesh 244
FR - Francia 122
BR - Brasile 98
HK - Hong Kong 68
DE - Germania 51
CA - Canada 47
FI - Finlandia 45
AR - Argentina 40
GB - Regno Unito 33
MX - Messico 25
JP - Giappone 21
IN - India 20
IQ - Iraq 17
NL - Olanda 15
CH - Svizzera 13
ID - Indonesia 13
ES - Italia 12
EC - Ecuador 11
UA - Ucraina 10
SE - Svezia 8
AT - Austria 7
IE - Irlanda 7
JM - Giamaica 7
PY - Paraguay 7
CO - Colombia 6
MA - Marocco 6
RU - Federazione Russa 6
TH - Thailandia 6
BE - Belgio 5
GR - Grecia 5
HN - Honduras 5
PK - Pakistan 5
SA - Arabia Saudita 5
VE - Venezuela 5
ZA - Sudafrica 5
CR - Costa Rica 4
GT - Guatemala 4
HR - Croazia 4
PH - Filippine 4
TR - Turchia 4
TT - Trinidad e Tobago 4
AL - Albania 3
AU - Australia 3
BB - Barbados 3
DZ - Algeria 3
EG - Egitto 3
KE - Kenya 3
KR - Corea 3
LT - Lituania 3
TN - Tunisia 3
UY - Uruguay 3
UZ - Uzbekistan 3
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
CL - Cile 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HU - Ungheria 2
LB - Libano 2
NI - Nicaragua 2
PA - Panama 2
PL - Polonia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BZ - Belize 1
CU - Cuba 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
GP - Guadalupe 1
HT - Haiti 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
MD - Moldavia 1
MG - Madagascar 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
SN - Senegal 1
TZ - Tanzania 1
Totale 18.558
Salva come PNG Salva come JPEG
Città #
Genova 6.805
Genoa 4.990
Rapallo 1.092
Vado Ligure 1.015
San Jose 360
Singapore 327
Ashburn 251
Ho Chi Minh City 114
Lauterbourg 107
Beijing 106
Hanoi 90
Hong Kong 67
Council Bluffs 66
New York 62
Santa Clara 44
Frankfurt am Main 43
Los Angeles 43
Helsinki 39
Milan 29
Chicago 23
Rome 23
Bordighera 21
Buffalo 20
Phoenix 20
Tokyo 20
Haiphong 17
Boardman 16
Turin 16
Orem 15
Brooklyn 14
Columbus 14
Da Nang 14
Dallas 13
Mexico City 13
Tianjin 13
Naples 12
São Paulo 12
Zurich 12
Amsterdam 10
Bologna 9
Can Tho 9
Cardiff 9
Houston 9
Montreal 9
Schiavon 9
The Dalles 9
Washington 9
Baghdad 8
Biên Hòa 8
Denver 8
Las Vegas 8
Miami 8
City of London 7
Dublin 7
Jacksonville 7
Philadelphia 7
Phủ Lý 7
Buenos Aires 6
Charlotte 6
Florence 6
Hải Dương 6
Lappeenranta 6
London 6
Palermo 6
Parma 6
Atlanta 5
Detroit 5
Kyiv 5
Madrid 5
Nha Trang 5
Paris 5
Poplar 5
Stockholm 5
Toronto 5
Boston 4
Bắc Ninh 4
Changsha 4
Dearborn 4
Dhaka 4
Ficarolo 4
Kingston 4
Manchester 4
Memphis 4
Minneapolis 4
Newark 4
Orlando 4
Queens 4
Quito 4
Rio de Janeiro 4
Rochester 4
San Antonio 4
Springfield 4
Westminster 4
Zagreb 4
Alexandria 3
Antwerp 3
Baltimore 3
Belo Horizonte 3
Boydton 3
Brasília 3
Totale 16.306
Salva come PNG Salva come JPEG
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 326
APO866 activity in hematologic malignancies: a preclinical in vitro study. 252
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 252
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 251
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 250
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 245
Autophagy in blood cancers: biological role and therapeutic implications. 241
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. 232
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 227
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 226
SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells 217
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 211
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 207
Ras-induced resistance to lapatinib is overcome by MEK inhibition 206
SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects 206
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells 204
Sirt6 regulates dendritic cell differentiation, maturation, and function 202
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 197
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 196
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. 193
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 191
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 188
Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response 188
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 187
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 186
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 185
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 182
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 180
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 180
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. 179
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 179
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation 177
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival 177
Evaluation of prognostic indices in elderly hospitalized patients 177
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 177
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 176
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 176
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis 176
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 175
Biological Insights into Myeloma and Other B Cell Malignancies 173
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 171
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 170
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 170
Abstract CT075: Fasting-mimicking diet and hormone therapy modulates metabolic factors to promote breast cancer regression and reduce side effects 169
Catastrophic NAD+ Depletion through Nampt Inhibition in Activated T Lymphocytes Reduces Demyelination and Disability in EAE. 167
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 166
Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8 166
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 165
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 163
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 161
Radiomics and artificial intelligence analysis of CT data for the identification of prognostic features in multiple myeloma 160
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 159
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma 158
Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach 157
Synthesis of Pyrrolidine 3,4-Diol Derivatives with Anticancer Activity on Pancreatic Tumor Cells 156
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 155
Synthesis and cancer growth inhibitory activities of 2-fatty-alkylated pyrrolidine-3,4-diol derivatives 155
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 154
New insights into biology of chronic myeloid leukemia: implications in therapy. 154
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 154
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. 154
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 153
Safety and feasibility of fasting‐mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment 151
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 150
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 149
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 148
Radiomics and artificial intelligence for outcome prediction in multiple myeloma patients undergoing autologous transplantation: A feasibility study with ct data 148
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 145
Nutrients in the Prevention of Alzheimer's Disease 145
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 144
SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice 142
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. 141
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 141
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 139
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 135
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 133
Harnessing Immune Response in Acute Myeloid Leukemia 131
Effect of Geriatric Comanagement in Older Patients Undergoing Surgery for Gastrointestinal Cancer: A Retrospective, Before-and-After Study 130
Depletion of the intracellular coenzyme NAD plus in activated T-cells ameliorates experimental autoimmune encephalomyelitis 130
Cyclic fasting bolsters cholesterol biosynthesis inhibitors' anticancer activity 129
Targeting Inflammation in Primary Cardiovascular Prevention 129
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 129
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 128
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. 125
Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. 121
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 120
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 119
Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review 118
Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. 116
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 112
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 112
Author Correction: Cyclic fasting bolsters cholesterol biosynthesis inhibitors' anticancer activity 111
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma 109
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies 109
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery 109
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells 108
Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report 107
Myeloma Spine and Bone Damage Score (MSBDS) on Whole-Body Computed Tomography (WBCT): Multiple Reader Agreement in a Multicenter Reliability Study 105
Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies 103
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 100
Totale 16.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.063
article - articoli 60.360
book - libri 0
conference - conferenze 1.703
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.250 43 63 100 156 63 102 69 247 72 110 63 162
2022/20231.379 145 153 17 142 228 177 9 82 200 28 175 23
2023/20241.006 36 92 33 144 96 182 79 96 31 21 72 124
2024/20252.977 124 186 63 236 288 289 276 563 89 176 328 359
2025/20266.013 670 227 599 520 707 371 747 277 409 613 416 457
2026/2027502 502 0 0 0 0 0 0 0 0 0 0 0
Totale 18.942